Separation media includes a membrane and a plurality of ligands immobilized on the membrane, the plurality of ligands comprising anion-exchange ligands, cation-exchange ligands, thiophilic ligands, hydrophilic ligands, hydrophobic interaction ligands, or a combination thereof. The separation media may be multimodal. The separation media may be configured for separation of target molecules comprising a nucleic acid, nucleotide, nucleoside, nucleobase, or an analogue or derivative thereof, from a reaction mixture. The separation media may be configured for use with organic solvents. A separation device includes the separation media. Materials including a nucleic acid, nucleotide, nucleoside, nucleobase, or an analogue or derivative thereof, may be purified at high speeds using the separation device.

A method for reducing a contaminating DNA content of a preparation containing AAV capsids and contaminating DNA, comprising the steps of a) Performing an extraction of DNA with a solid phase bearing positive charges at its surface said solid phase is contacted with the preparation at a pH of 7.0±1.0, and a salt concentration of 10 mM to 200 mM yielding a first fraction, (b) Diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction, (c) Treating the second fraction with DNase, (d) Diafiltering the DNase treated second fraction obtained by step c) by a second tangential flow, (e) filtration to a buffer with pH of 7.0±1.0, and a salt concentration of 10 mM to 20 mM to yield a third fraction, and optionally (f) Concentrating the third fraction by tangential flow filtration before supplemental chromatography.

A device and method for in-line homogenizing a non-uniform feed stream is described herein, which includes a plug flow reactor (PFR), a bypass line, and a pump in a closed-circuit flow path that allows for rapid homogenization of the non-uniform feed stream.

In accordance with the invention, provided herein are methods for purifying recombinant adeno-associated (rAAV) vector particles.

A test device is provided that can comprise: a housing accommodating a chromatography support, wherein the housing comprises: a supporting part that supports a container accommodating a liquid used for chromatography. A method is provided for performing chromatography using the test device.

Methods for preparing CD7-negative, CD3-positive T cells, which optionally express a chimeric antigen receptor, are provided as is a method of using such cells in a method for treating cancer, in particular a CD7+ cancer. In one aspect, the invention provides a method for preparing a population of CD7-negative, CD3-positive T cells by (a) performing a first selection by depleting, from a population of primary immune cells, cells that express CD7 thereby generating a population of CD7-negative cells; (b) performing a second selection by enriching, from the population of CD7-negative cells, T cells that express CD3 thereby generating a population of CD7-negative and CD3-positive T cells, and (c) incubating the population of CD7-negative and CD3-positive T cells in a culture vessel under stimulating conditions, thereby generating stimulated CD7-negative, CD3-positive T cells.

Site-specific modifications of proteins are desirable in biotechnological applications such as biopharmaceuticals, immunotherapy, vaccines, and are useful in chemical biology. Gluconoylation is a non-enzymatic, covalent, post-translational modification commonly observed on N-terminal His-Tags bearing proteins. We synthesized glucono-1,5-lactone derivatives, including azido variants for selective acylation. High yield acylation is achieved by simply mixing derivatives with target protein amidst diverse conditions of temperatures, aqueous buffers, excipients, or complex cell lysate.

Methods of maintaining narrow residence time distributions in continuous flow systems, particularly applicable to virus inactivation such as during a protein purification process. Fluid sample is introduced into an axial flow channel and caused to flow therein in discrete packets or zones to minimize residence time distribution and axial dispersion. Embodiments described herein obviate or minimize the need for using large tanks or reservoirs for performing virus inactivation during a protein purification process; reduce the overall time required for virus inactivation, and/or reduce the overall physical space required to perform the virus inactivation operation during a protein purification process, which in turn reduces the overall footprint for the purification process.

The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of plasmaproteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.

A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.